Cancer and diabetes are debilitating diseases with the highest impact on health outcomes worldwide. The incidence of these two diseases coexisting is not a chance occurrence. The interaction between diabetes and cancer therapies strongly affects patient treatment outcome. Patients with diabetes have a higher risk of cancer. Commonality in endocrine treatment narrows the gap between the two diseases.

We invite authors to submit original research and review articles that address the interrelationship between cancer and diabetes with a focus on the changing metabolic pathways. We are particularly interested in combined modality treatment for endocrine-resistant disorders. Current concepts in cancer and diabetic treatment using pharmogenetics, stem cells, and viral and nonviral gene therapy animal models and clinical strategies are encouraged. Potential topics include, but are not limited to:

• The link between cancer and diabetes
• Advances in gene therapy for diabetes and/or cancer
• Diabetes and the risk of cancer
• Diabetic treatments and cancer prognosis
• Inflammation, cancer, and diabetes
• The effects of cancer therapies on the diabetic patient
• Combinational therapies to combat endocrine-related disorders: cancer and/or diabetes
• Epidemiological challenges of cancer treatment and diabetic risk
• Inflammatory growth factor signal underlying obesity/diabetes and cancer
• Endocrine resistance and recurrence in cancer: breast, prostate, and ovarian

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/pathology/endoc/ according to the following timetable: